MERCOLA
Take Control of Your Health

Geranylgeraniol and the Mevalonate Pathway — A Second Area of Research Interest

Analysis by Dr. Joseph Mercola | May 17, 2026

STORY AT-A-GLANCE

- Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a complication affecting patients taking osteoporosis and cancer medications like Fosamax, Boniva, and Zometa
- Bisphosphonates work by the same mechanism as statins — they inhibit the mevalonate pathway, which means they cause the same depletion of geranylgeraniol (GG) that leads to statin muscle problems
- Researchers are investigating the role of GG in mevalonate pathway support for people taking bisphosphonates
- Laboratory studies have examined GG's biochemical effects on osteoblasts (bone-building cells), osteoclasts (bone-remodeling cells), fibroblasts, and endothelial cells in bisphosphonate-exposed models — findings are preliminary and have not been tested in human clinical trials
- A 2024 study reported that GG incorporated into bone cement supported osteoclast function and bone remodeling in an animal model of medication-related osteonecrosis of the jaw

If you've been following my work, you may have recently read my article on geranylgeraniol (GG, or the chemistry-style abbreviation GGOH, which stands for geranylgeraniol alcohol) and how it's being studied for statin-induced muscle symptoms, particularly in cases where CoQ10 has not provided relief.

Today, I want to share another area of research where this same compound has been studied — bisphosphonate-related osteonecrosis of the jaw, or BRONJ for short. And research on GG's role in the mevalonate pathway may be relevant here as well.

What Are Bisphosphonates and Who Takes Them?

Bisphosphonates are a class of drugs prescribed primarily for osteoporosis and for preventing bone complications in cancer patients. You may know them by brand names like Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), and Zometa or Reclast (zoledronic acid).

These drugs work by inhibiting osteoclasts, the cells responsible for breaking down old bone. By suppressing bone resorption, bisphosphonates can increase bone density and reduce fracture risk. For cancer patients with bone metastases, they can help prevent skeletal complications.

Millions of people take these medications. In fact, bisphosphonates are among the most commonly prescribed drugs for postmenopausal women with osteoporosis. But like all drugs, they come with risks, and one of the most serious is osteonecrosis of the jaw.

The Horror of Jaw Bone Death

Osteonecrosis literally means "bone death." When it occurs in the jaw, the bone tissue dies and becomes exposed through the gums, failing to heal. Patients develop painful, exposed bone in their mouth that can become infected, lead to tooth loss, and in severe cases require surgical removal of portions of the jaw.

The condition is diagnosed when a patient has exposed jaw bone that doesn't heal within eight weeks, has a history of taking bisphosphonates or similar medications, and has no history of radiation therapy to the jaw area. What makes BRONJ particularly insidious is that, once jaw bone damage is established, treatment options are limited to managing symptoms, controlling infection, and in some cases, surgical debridement or removal of dead bone.

The condition often develops after dental procedures — tooth extractions, implant placement, or other invasive dental work. This is why dentists now routinely ask patients about bisphosphonate use before performing procedures, and why some recommend "drug holidays" before dental surgery.

These overlapping mechanisms have prompted researchers to ask whether compounds investigated in the context of statin-induced muscle symptoms might also be relevant to bisphosphonate-associated bone biology.

Same Mechanism, Same Biochemical Pathway

Here's the key insight that connects these two seemingly different conditions: Bisphosphonates and statins work through the same biochemical pathway.

Both drug classes inhibit enzymes in the mevalonate pathway. Statins block HMG-CoA reductase at the top of the pathway. Bisphosphonates — specifically the nitrogen-containing bisphosphonates like zoledronic acid — block farnesyl pyrophosphate synthase further down the pathway.

The end result is the same: depletion of geranylgeranyl pyrophosphate (GGPP), the activated form of GG. And when GGPP is depleted, the process of protein prenylation — essential for normal cell function—is impaired.

In muscle cells, this manifests as the muscle pain, weakness, and fatigue that statin patients experience. In the jaw bone, where there's constant remodeling activity and exposure to oral bacteria, GGPP depletion is thought to contribute to impaired healing; the full pathogenesis of BRONJ is multifactorial.

A 2022 review published in Frontiers in Pharmacology[1] explained the connection: "Nitrogen-containing bisphosphonates suppress osteoclastic resorption by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, leading to deficiency of the substrate for GTPase prenylation. The bone remodeling process is uncoupled, subsequently impairing bone healing and causing ONJ."

The review authors proposed GG as a candidate for further investigation, citing its role as a substrate for GTPase prenylation. These authors' proposals remain hypotheses pending human clinical evaluation.

The Research on GG and Bisphosphonate-Affected Cells

Multiple studies have examined GG's effects on bisphosphonate-treated cells, reporting findings across several cell types critical to jaw bone health.

A 2011 study published in Oral Oncology[2] was among the first to show that GG could reverse the negative biological effects of nitrogen-containing bisphosphonates on endothelial cells (which form blood vessels), fibroblasts (which form connective tissue), and osteogenic cells (which form bone). The researchers reported restored viability and migration capacity in bisphosphonate-exposed cell models after GG treatment.

A 2021 study published in Frontiers in Cell and Developmental Biology[3] investigated the specific mechanism by which bisphosphonates cause jaw bone problems. The researchers found that zoledronic acid (a potent bisphosphonate) both promoted the death of osteocytes (bone cells) and inhibited the ability of macrophages to clear dead cells — a process called efferocytosis that's essential for proper healing.

Crucially, the study found that "supplement with geranylgeraniol (GGOH), a substrate analog for geranylgeranylation of Rac1, could restore Rac1 homeostasis and rescue macrophage efferocytosis." Rac1 (along with a closely related protein called Rac2) acts like an on-off switch that helps immune cells move, attach to damaged tissue, and clear away dead cells so healing can occur.

These proteins must attach to cell membranes to work properly, and they need GG to do that. When bisphosphonates block this process, Rac signaling breaks down and immune cells cannot clean up damaged tissue. In the cell models studied, GG was observed to restore Rac1 signaling activity — the specific pathway bisphosphonates had disrupted — allowing macrophages to resume clearing damaged tissue.

A 2020 study[4] examined the effects of zoledronic acid and GG on angiogenic (blood vessel-forming) gene expression in human osteoclasts. The researchers found that bisphosphonate treatment altered the expression of multiple genes involved in blood vessel formation — a key factor in bone healing. Addition of GG resulted in reduction of these altered gene expressions, suggesting it could help normalize the angiogenic response.

A 2024 Animal Study: GG-Infused Bone Cement

A 2024 study published in the Journal of Oral Biology and Craniofacial Research[5] tested GG in an actual model of medication-related osteonecrosis of the jaw (MRONJ). Researchers incorporated GG into bone cement pellets and tested their effects both in cell culture and in animals. They found that GG released from the bone cement supported osteoclast survival and metabolic activity and promoted resorption of calcified substrate.

In the animal model, the authors reported that GG "limited the effects of the bisphosphonate and promoted healing," and concluded that "these initial findings point to GGOH in a bone cement carrier as a useful therapeutic approach to prevent or mitigate the pathogenesis of MRONJ."

While this specific delivery method (bone cement) is a clinical application that would need to be performed by a dental surgeon, across these early studies, laboratory and animal findings have consistently pointed in the same direction — though human clinical data are not yet available to confirm whether this translates to meaningful outcomes in patients.

The Connection to Statin Myopathy

If you read my previous article on GG for statin-induced muscle problems, you'll recognize the pattern. Both statins and bisphosphonates:

- Inhibit the mevalonate pathway

- Deplete geranylgeranyl pyrophosphate (GGPP)
- Impair protein prenylation
- Cause tissue damage (muscle or bone) through this mechanism
- Have been the subject of GG supplementation research, given the compound's role in replenishing depleted GGPP

Essentially, these drugs work through the same fundamental mechanism, which is why they cause related problems and why researchers have investigated the same compound in both contexts.

The research on GG in the context of statin myopathy is more advanced, with multiple in vivo studies and meta-analyses examining outcomes in patients for whom CoQ10 had not provided relief — pointing to the GGPP repletion mechanism rather than the CoQ10 pathway as the relevant target.

In the context of BRONJ, the research on GG is still developing, with most studies being in vitro (cell culture) or in animal models. But the consistency of the findings across both conditions is consistent with the underlying mechanism.

Populations Studied in GG Research

Researchers studying GG depletion have identified several populations that appear in the clinical literature as subjects of interest.

Studies on BRONJ have included patients receiving bisphosphonate therapy for osteoporosis, including drugs such as Fosamax, Boniva, and Actonel, with particular attention to those undergoing dental procedures, where BRONJ risk is elevated. These studies examined biochemical markers and cellular responses; they did not establish clinical benefit.

Tooth extractions and implant placement have been described as procedural triggers for BRONJ. Researchers have examined whether GG status before, during, and after such procedures may influence outcomes. Cancer patients receiving high-dose intravenous bisphosphonate therapy, such as Zometa, represent another population studied in the BRONJ literature, given the higher incidence rates observed in oncology settings compared to osteoporosis treatment doses.

Researchers have also noted that statin and bisphosphonate medications share a biochemical pathway through which GG depletion occurs. Because both drug classes are commonly prescribed together in older adult populations, some investigators have suggested that concurrent use may compound depletion, a hypothesis that has informed study design in this area; clinical implications of concurrent use have not been established.

These findings are from research conducted in laboratory and animal models. Results may not apply to all individuals.

GG Supplementation Research: Doses, Timing, and Safety Profile

Researchers investigating GG supplementation in the context of bisphosphonate use have examined a range of study parameters. The following reflects study parameters reported in the published literature, not a consumer protocol. In published studies, GG has been administered at doses ranging from 150 mg to 300 mg daily.

Studies have examined GG status in relation to dental procedures, including tooth extractions and implant placement, given that these are recognized procedural triggers for BRONJ. Researchers have also noted that bisphosphonates can persist in bone tissue for years, which has been a factor in how long-term GG depletion in this population has been studied.

In the laboratory and animal studies conducted to date, GG has generally been well-tolerated. However, comprehensive long-term human clinical safety data are not yet available.

This section summarizes study parameters and general findings. It is not medical advice. Anyone taking bisphosphonates should discuss supplementation decisions with their physician and dentist.

A Unified Approach to Mevalonate Pathway Support

The story of geranylgeraniol is really a story about understanding biochemistry rather than just treating symptoms. Conventional medicine tends to treat statin myopathy and bisphosphonate jaw necrosis as completely separate problems, but researchers studying the mevalonate pathway recognize them as two expressions of the same underlying depletion, occurring in different tissues. That shared biochemical lens is what makes GG relevant to both.

This is the kind of integrative thinking that conventional medicine often misses. The underlying mechanism is well-established, and while the clinical research is still developing, early findings and the safety profile to date make it a reasonable area to explore with a health care provider. Whether that exploration involves supplementation specifically is a determination that should be made collaboratively with a provider who has reviewed your full medication list.

FAQ

Q: What is bisphosphonate-related osteonecrosis of the jaw (BRONJ)?

A: BRONJ is a serious condition in which sections of jaw bone lose blood supply, die, and fail to heal. It occurs in some people who take bisphosphonate drugs for osteoporosis or cancer, especially after dental procedures such as tooth extractions. Once established, the condition is difficult to manage clinically, which has motivated research into upstream biochemical factors.

Q: How do bisphosphonates cause jaw bone damage?

A: Bisphosphonates block enzymes in the mevalonate pathway, a metabolic pathway your body uses to produce essential compounds. This blockade depletes geranylgeranyl pyrophosphate (GGPP), which cells need for protein prenylation, a process required for normal bone remodeling, immune cleanup, blood vessel growth, and tissue repair.

Q: What is the relevance of geranylgeraniol (GG) in BRONJ research?

A: GG is a precursor to GGPP, a compound the body uses for protein prenylation — a normal cellular process involved in bone, muscle, and immune cell function. Because the mevalonate pathway is the same pathway bisphosphonates act on, researchers have examined GG as a research subject in laboratory and animal models.

Q: What does research show about GG in bone-related cell models?

A: Cell and animal studies report that GG reduced bisphosphonate-induced cell death in laboratory models, restored immune cell cleanup activity in cell culture models, and normalized blood vessel-related gene activity. A 2024 animal study reported GG delivered through bone cement promoted bone remodeling and healing in a model of medication-related osteonecrosis of the jaw.

Q: Which populations have been studied in GG research?

A: Clinical literature has focused on populations taking bisphosphonates for osteoporosis or cancer, particularly those undergoing dental procedures, as subjects of interest in GG research. Human clinical trials remain limited, so you should

discuss supplementation with your dentist and physician before use.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your health regimen.

Sources and References

- [1] Front Pharmacol. 2022 May 4;13:878556
- [2] Oral Oncol. 2011 Mar;47(3):195-201
- [3] Front Cell Dev Biol. 2021 Nov 3;9:770899
- [4] J Oral Sci. 2020;62(1):79-83
- [5] J Oral Biol Craniofac Res. 2024 Mar-Apr;14(2):126-132